Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Reiterated by Cantor Fitzgerald

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report)'s stock had its "overweight" rating reissued by stock analysts at Cantor Fitzgerald in a report issued on Tuesday, Benzinga reports. They currently have a $13.00 price objective on the biopharmaceutical company's stock.

Several other equities research analysts have also recently issued reports on MRNS. Truist Financial reiterated a "buy" rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a "buy" rating to a "neutral" rating in a report on Wednesday, August 14th. StockNews.com raised shares of Marinus Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, September 18th. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Finally, Oppenheimer raised Marinus Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $6.00 price target for the company in a research note on Monday. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Marinus Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $8.83.

Marinus Pharmaceuticals Price Performance

Marinus Pharmaceuticals stock traded up $0.27 during mid-day trading on Tuesday, hitting $1.90. The stock had a trading volume of 2,966,874 shares, compared to its average volume of 1,135,649. Marinus Pharmaceuticals has a one year low of $1.05 and a one year high of $11.26. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. The firm has a market capitalization of $104.37 million, a P/E ratio of -0.68 and a beta of 1.13. The firm's 50 day moving average is $1.38 and its 200 day moving average is $2.73.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.01). The business had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same period last year, the company earned ($0.61) EPS. On average, sell-side analysts forecast that Marinus Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC increased its position in shares of Marinus Pharmaceuticals by 31.4% during the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company's stock valued at $37,431,000 after purchasing an additional 990,607 shares during the last quarter. Vanguard Group Inc. increased its position in Marinus Pharmaceuticals by 5.0% during the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company's stock valued at $25,366,000 after acquiring an additional 132,689 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at $813,000. Renaissance Technologies LLC bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter worth about $727,000. Finally, Superstring Capital Management LP bought a new stake in shares of Marinus Pharmaceuticals in the 4th quarter worth about $5,027,000. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.